<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">MRP</journal-id><journal-title-group><journal-title>Medical Research and Practice</journal-title></journal-title-group><issn>2993-9690</issn><eissn>2993-9704</eissn><publisher><publisher-name>Art and Technology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.61369/MRP.2026090032</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>六味地黄丸/RXRa/PI3K-AKT 轴向调控前列腺癌的作用机制</title><url>https://artdesignp.com/journal/MRP/4/9/10.61369/MRP.2026090032</url><author>何炜铖,彭石云,徐霖,汪涛,高丽云</author><pub-date pub-type="publication-year"><year>2026</year></pub-date><volume>4</volume><issue>9</issue><history><date date-type="pub"><published-time>2026-09-20</published-time></date></history><abstract>六味地黄丸（LWDHP）在临床实践中展现出对抗前列腺癌的潜在疗效，然而其背后的作用机制仍未阐明。本研究整合网络药理预测、生物信息分析及实验验证，旨在揭示该方剂发挥抗癌功效的分子基础。通过筛选LWDHP 所含活性组分，获取药物靶点与疾病相关靶标的交集；实施网络拓扑结构解析与功能富集评估；并借助蛋白质印迹法检测关键蛋白的表达水平。最终鉴定出69种具有生物活性的化学实体，以及186个核心作用基因；其中槲皮素被确认为主要活性成分，重要靶点涵盖RXRa、PTGS2与HSP90AA1；核心基因富集于PI3K-Akt 和TNF 通路。实验证实，LWDHP 下调前列腺癌细胞RXRa 表达并改变AKT 磷酸化水平。LWDHP 通过&amp;ldquo;多成分- 多靶点- 多通路&amp;rdquo;协同模式，尤其调节RXRa 介导的PI3K-Akt 信号轴，发挥抗前列腺癌效应。</abstract><keywords>六味地黄丸,前列腺癌,RXRa,PI3K-Akt 信号通路</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1]LIF,YUY,JIANGM,etal.Targetsforimprovingprostatetumorresponsetoradiotherapy[J].EuropeanJournalofPharmacology,2025,986:177149.[2]TSAIJ-J,YENC-Y,HSUC-H,etal.ImmunomodulatoryeffectsofmodifiedLiu-Wei-Di-Huang-WantraditionalChinesemedicineonallergicasthmaticmice[J].Allergy,Asthma&amp;amp;ClinicalImmunology,2023,19(1):35.[3]LIS,CHENJ,HUY,etal.networkpharmacologyandAI[J].JEthnopharmacol,2023,307:116260.[4]WUZ,YUX,ZHANGS,etal.TheroleofPI3K/AKTsignalingpathwayingallbladdercarcinoma[J].AmericanJournalofTranslationalResearch,2022,14(7):4426.[5]YEY,LIUM,WUF,etal.TRMT6promoteshepatocellularcarcinomaprogressionthroughthePI3K/AKTsignalingpathway[J].EuropeanJournalofMedicalResearch,2023,28(1):48.[6]ZHANX,LIH,JINJ,etal.NetworkpharmacologyandexperimentalvalidationtoexploretheroleandpotentialmechanismofLiuweiDihuangDecoctioninprostatecancer[J].BMCcomplementarymedicineandtherapies,2024,24(1):284.[7]WANGR,QUZ,LVY,etal.ImportantrolesofPI3K/AKTsignalingpathwayandrelevantinhibitorsinprostatecancerprogression[J].Cancermedicine,2024,13(21):e70354.[8]TORTORELLAE,GIANTULLIS,SCIARRAA,etal.ARandPI3K/AKTinprostatecancer:ataleoftwointerconnectedpathways[J].InternationalJournalofMolecularSciences,2023,24(3):2046.[9]PANDZICD,SUPICG,MISICD,etal.TheimpactofgeneticvariationsinretinoidXreceptoralphaontheriskandprognosisofHPV ‐negativeoralcarcinoma[J].EuropeanJournalofOralSciences,2025,133(3):e70015.[10]CAOY,YIY,HANC,etal.NF-&amp;kappa;Bsignalingpathwayintumormicroenvironment[J].Frontiersinimmunology,2024,15:1476030.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
